SOHO 2024 | The prognostic value of MRD and PB versus BM measurements in T-ALL
Josep-Maria Ribera, MD, PhD, Institut Català d’Oncologia Badalona, Barcelona, Spain, discusses the prognostic value of measurable residual disease (MRD) in T-cell acute lymphoblastic leukemia (T-ALL). Prof. Ribera also underlines the benefits of peripheral blood (PB) MRD measurements being equally sensitive to bone marrow (BM) MRD measurements. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, MRD in T-ALL has a prognostic value and really MRD is used for the decision to transplant or not after consolidation. The clearance of MRD in T-ALL is slower than in B-cell precursor ALL, but anyway it’s a very good tool to decide further therapy. What is important is that we can use peripheral blood assessment of MRD with the equal sensitivity and results as bone marrow assessment. And this is good news for patients...
Well, MRD in T-ALL has a prognostic value and really MRD is used for the decision to transplant or not after consolidation. The clearance of MRD in T-ALL is slower than in B-cell precursor ALL, but anyway it’s a very good tool to decide further therapy. What is important is that we can use peripheral blood assessment of MRD with the equal sensitivity and results as bone marrow assessment. And this is good news for patients. So they don’t need repeated bone marrow aspirates. It can be substituted safely by peripheral blood assessments.
Read more...
